-
Thyroid hormone induces ossification and terminal maturation in a preserved OA cartilage biomimetic model Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-25 N. M. Korthagen, E. Houtman, I. Boone, R. Coutinho de Almeida, K. Sivasubramaniyan, R. Mahdad, R. G. H. H Nelissen, Y. F. M. Ramos, M. A Tessari, I. Meulenbelt
To characterize aspects of triiodothyronine (T3) induced chondrocyte terminal maturation within the molecular osteoarthritis pathophysiology using the previously established T3 human ex vivo osteochondral explant model. RNA-sequencing was performed on explant cartilage obtained from OA patients (n = 8), that was cultured ex vivo with or without T3 (10 ng/ml), and main findings were validated using
-
Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-25 Seulkee Lee, Seonyoung Kang, Hyungjin Kim, Jaejoon Lee, Min-Ji Kim, Hoon-Suk Cha
We aimed to investigate whether there are sex differences in disease activity measures among patients with axial spondyloarthritis (axSpA) and to determine any potential impact on the assessment of treatment responses to tumor necrosis factor alpha inhibitors (TNFi). Using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry data, we compared sex differences in changes
-
Retraction Note: Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-19 Yanfeng Wu, Mingliang Ren, Rui Yang, Xinjun Liang, Yuanchen Ma, Yong Tang, Lin Huang, Jichao Ye, Keng Chen, Peng Wang, Huiyong Shen
Retraction Note: Arthritis Res Ther 13, R29 (2011) https://doi.org/10.1186/ar3257 The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding highly similar images in Fig. 1A-C, specifically: Panels A2 and C2 appear highly similar, with 180 degree rotation. Panels A3 and C3 appear to overlap. Panels B4 and C4 appear to overlap. The authors have stated that incorrect
-
Osteoarthritis and hypertension: observational and Mendelian randomization analyses Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-17 Zhi-Jie Yang, Yuan Liu, Yan-Li Liu, Bin Qi, Xin Yuan, Wan-Xin Shi, Liu Miao
The association between osteoarthritis (OA) and hypertension is a subject of ongoing debate in observational research, and the underlying causal relationship between them remains elusive. This study retrospectively included 24,871 participants in the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2020. Weighted logistic regression was performed to investigate the connection
-
Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-17 Zento Yamada, Sei Muraoka, Mai Kawazoe, Wataru Hirose, Hajime Kono, Shinsuke Yasuda, Takahiko Sugihara, Toshihiro Nanki
We aimed to reveal the effect of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients, 3-year efficacy for arthritis, and safety in a population of older vs. younger patients. In this open-label, prospective, observational study, patients were stratified into four groups: younger (20–64 years old) and older (≥ 65 years) patients taking ABT (AY and AO) and conventional synthetic
-
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-12 Emily E. Holladay, Amy S. Mudano, Fenglong Xie, Jingyi Zhang, Ted R. Mikuls, Brian LaMoreaux, Lissa Padnick-Silver, Jeffrey R. Curtis
Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation. We conducted a retrospective analysis of gout patients who discontinued pegloticase using the Rheumatology Informatics System for Effectiveness (RISE) registry
-
Deregulation in adult IgA vasculitis skin as the basis for the discovery of novel serum biomarkers Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-12 Matija Bajželj, Matjaž Hladnik, Rok Blagus, Vesna Jurčić, Ana Markež, Tanya Deniz Toluay, Snežna Sodin-Šemrl, Alojzija Hočevar, Katja Lakota
Immunoglobulin A vasculitis (IgAV) in adults has a variable disease course, with patients often developing gastrointestinal and renal involvement and thus contributing to higher mortality. Due to understudied molecular mechanisms in IgAV currently used biomarkers for IgAV visceral involvement are largely lacking. Our aim was to search for potential serum biomarkers based on the skin transcriptomic
-
Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-12 Shuping Wei, Haiyun Shen, Yidan Zhang, Chunrui Liu, Shoushan Li, Jing Yao, Zhibin Jin, Hongliang Yu
We attempted to identify abnormal immune cell components and signaling pathways in lupus nephritis (LN) and to identify potential therapeutic targets. Differentially expressed genes (DEGs) between LN and normal kidney tissues were identified from bulk transcriptome data, and functional annotation was performed. The phenotypic changes in macrophages and aberrant intercellular signaling communications
-
Usability and preliminary effectiveness of an app-based physical activity and education program for people with hip or knee osteoarthritis – a pilot randomized controlled trial Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-10 F. Weber, C. Kloek, S. Stuhrmann, Y. Blum, C. Grüneberg, C. Veenhof
Hip and knee osteoarthritis (OA) are highly prevalent worldwide. The guidelines recommend physical activity and education as the core treatments for osteoarthritis. Digital health has the potential to engage people in physical activity and disease management. Therefore, we conducted a pilot trial to assess the usability and preliminary effectiveness of an app-based physical activity and education program
-
Anxiety and depression symptoms in adolescents and young adults with juvenile idiopathic arthritis: results of an outpatient screening Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-10 Florian Milatz, Jens Klotsche, Martina Niewerth, Claudia Sengler, Daniel Windschall, Tilmann Kallinich, Frank Dressler, Ralf Trauzeddel, Reinhard W. Holl, Ivan Foeldvari, Normi Brück, Svenja Temming, Toni Hospach, Petra Warschburger, Rainer Berendes, Gabriele Erbis, Jasmin B. Kuemmerle-Deschner, Frank Weller-Heinemann, Johannes-Peter Haas, Annabel S. Müller-Stierlin, Agnes Mutter, Thomas Meissner,
Previous studies have shown that growing up with rheumatic conditions can fuel dissatisfaction and psychological distress, which in turn affects disease self-management and treatment adherence. Primary objective of this study was to estimate the prevalence of anxiety and depression symptoms in adolescents and young adults (AYA) with juvenile idiopathic arthritis (JIA) and to identify correlates of
-
Correction: Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-10 Stefano Soldano, Vanessa Smith, Paola Montagna, Emanuele Gotelli, Rosanna Campitiello, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Andrea Cere, Maurizio Cutolo
Correction: Arthritis Res Ther 26, 74 (2024) https://doi.org/10.1186/s13075-024-03308-7 Following publication of the original article [1], the authors reported that the equal contribution statement was missing. The following statement has been added “Stefano Soldano and Vanessa Smith contributed equally to the manuscript as first authors.” The original article [1] has been updated. Soldano S, Smith
-
Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-08 Isabelle Koné-Paut, Sophie Georgin-Lavialle, Alexandre Belot, Magali Jover, Mathilde Pouriel, Laure Lacoin, Pascal Pillet, Véronique Hentgen
Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS). This study used the JIR cohort, a multicentre international registry created in 2013 to collect data on patients with juvenile inflammatory
-
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-03 Corrado Campochiaro, Nicola Farina, Giacomo De Luca, Veronica Batani, Giorgia Trignani, Davide Vignale, Anna Palmisano, Marco Matucci-Cerinic, Lorenzo Dagna
Idiopathic inflammatory myopathies (IIM) represent a rare and heterogenous group diseases, and their treatment is not fully defined yet. According to previous small case series, the combination of mycophenolate mofetil (MMF) and rituximab (RTX) may be effective in controlling difficult-to-treat patients. Our aim was to further explore the efficacy and safety of this combined approach in patients with
-
Specific isoforms of the ubiquitin ligase gene WWP2 are targets of osteoarthritis genetic risk via a differentially methylated DNA sequence Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-03 Jack B. Roberts, Olivia L.G. Boldvig, Guillaume Aubourg, S. Tanishq Kanchenapally, David J. Deehan, Sarah J. Rice, John Loughlin
Transitioning from a genetic association signal to an effector gene and a targetable molecular mechanism requires the application of functional fine-mapping tools such as reporter assays and genome editing. In this report, we undertook such studies on the osteoarthritis (OA) risk that is marked by single nucleotide polymorphism (SNP) rs34195470 (A > G). The OA risk-conferring G allele of this SNP associates
-
Peptidoglycan in osteoarthritis synovial tissue is associated with joint inflammation Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-27 Meaghan N Holub, Amanda Wahhab, Joseph R Rouse, Rebecca Danner, Lauren G Hackner, Christine B Duris, Mecaila E McClune, Jules M Dressler, Klemen Strle, Brandon L Jutras, Adam I Edelstein, Robert B Lochhead
Peptidoglycan (PG) is an arthritogenic bacterial cell wall component whose role in human osteoarthritis is poorly understood. The purpose of this study was to determine if PG is present in synovial tissue of osteoarthritis patients at the time of primary total knee arthroplasty (TKA), and if its presence is associated with inflammation and patient reported outcomes. Intraoperative synovial tissue and
-
Deficiency of peripheral CLA+ Tregs and clinical relevance in Behcet’s syndrome Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-21 Jiachen Li, Feng Sun, Danxue Zhu, Yuke Hou, Gong Cheng, Ping Wang, Xu Jin, Wenyan Zhou, Xiaolin Sun, Zhanguo Li, Tian Liu
Autoimmune responses have been suggested to involvement in patients with Behcet’s syndrome (BS). There has been growing attention towards the roles of cutaneous lymphocyte antigen (CLA)+ regular T cells (Tregs) in autoimmune diseases. The role of CLA+ Tregs in BS is still uncertain. This study aims to clarify the impact of CLA+ Tregs on BS. We collected peripheral blood from a total of 107 patients
-
Patients with systemic sclerosis and low CD4 numbers after autologous stem cell transplantation have a favorable outcome Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-20 Ann-Christin Pecher, Reinhild Klein, Ina Koetter, Marieke Wagner, Wichard Vogel, Stefan Wirths, Claudia Lengerke, Joerg Christoph Henes
Treatment with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (aHSCT) is an intensive treatment option for patients with severe forms of systemic sclerosis (SSc). Even though associated with a high treatment related mortality, the results in this high-risk population are generally favourable. The knowledge on the potential mechanism of action of this therapy and
-
Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-20 Stefano Soldano, Vanessa Smith, Paola Montagna, Emanuele Gotelli, Rosanna Campitiello, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Andrea Cere, Maurizio Cutolo
Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by vasculopathy and progressive fibrosis of skin and several internal organs, including lungs. Macrophages are the main cells involved in the immune-inflammatory damage of skin and lungs, and alternatively activated (M2) macrophages seem to have a profibrotic role through the release of profibrotic cytokines (IL10) and
-
Targeting STAT6-mediated synovial macrophage activation improves pain in experimental knee osteoarthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-20 Garth Blackler, Yue Lai-Zhao, Joseph Klapak, Holly T. Philpott, Kyle K. Pitchers, Andrew R. Maher, Benoit Fiset, Logan A. Walsh, Elizabeth R. Gillies, C. Thomas Appleton
Pain from osteoarthritis (OA) is one of the top causes of disability worldwide, but effective treatment is lacking. Nociceptive factors are released by activated synovial macrophages in OA, but depletion of synovial macrophages paradoxically worsens inflammation and tissue damage in previous studies. Rather than depleting macrophages, we hypothesized that inhibiting macrophage activation may improve
-
The prevalence of sarcopenia in spondyloarthritis patients: a meta-analysis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-16 Jiawen Hu, Yiwen Wang, Xiaojian Ji, Yinan Zhang, Kunpeng Li, Feng Huang
Spondyloarthritis (SpA) is a chronic inflammatory disorder that affects sacroiliac joints and spine, resulting in substantial disability. Sarcopenia, characterized by the loss of muscle mass and function, is a prevalent comorbidity in various chronic diseases. However, the exact prevalence of sarcopenia in SpA patients remains uncertain. The objective of this study is to conduct a systematic review
-
TfR1 mediated iron metabolism dysfunction as a potential therapeutic target for osteoarthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-16 Wenchao Wang, Zhenkai Ma, Xuemin Feng, Jiabin Ren, Shengyao Sun, Yuandong Shao, Weimin Zhang, Xiaoxia Yang, Jiaming Zhang, Xingzhi Jing
Transferrin receptor-1 (TfR1) plays important roles in controlling cellular iron levels, but its role in OA pathology is unknown. Herein we aim to investigate the role of TfR1 in OA progression and its underlying mechanisms. TfR1 expression in cartilage during OA development were examined both in vivo and in vitro. Then IL-1β was used to induce chondrocytes degeneration in vitro and TfR1 siRNA was
-
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-16 Sabrina Pollastro, Anne Musters, Giulia Balzaretti, Ilse Niewold, Barbera van Schaik, Signe Hässler, Catharina M. Verhoef, Marc Pallardy, Antoine van Kampen, Xavier Mariette, Niek de Vries
Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself. The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage
-
Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-14 Mojca Zajc Avramovič, Nataša Toplak, Gašper Markelj, Nina Emeršič, Tadej Avčin
To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children’s Hospital Ljubljana, Slovenia, from January 2015 to May 2023 in children with JIA, clinically presenting as oligoarthritis receiving intra-articular
-
Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-14 Lisa Christ, Seraphina Kissling, Axel Finckh, Benjamin A. Fisher, Sabine Adler, Britta Maurer, Burkhard Möller, Florian Kollert
To investigate the clinical phenotype and treatment response in patients with rheumatoid arthritis (RA) with and without concomitant Sjögren’s disease (SjD). In this observational cohort study, patients with RA from the Swiss Clinical Quality Management in Rheumatic Diseases registry were categorised according to the presence or absence of SjD. To assess treatment effectiveness, drug retention of tumor
-
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-12 Jun Li, Liying Peng, Lijun Wu, Yufang Ding, Xinwang Duan, Jian Xu, Wei Wei, Zhen Chen, Cheng Zhao, Min Yang, Nan Jiang, Shangzhu Zhang, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng, Yan Zhao, Jiuliang Zhao
To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP). This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count<100 × 109/L. Demographic characteristics, platelet count, clinical manifestations, disease activity, and autoantibody profiles were collected
-
Streamlined, single-step non-viral CRISPR-Cas9 knockout strategy enhances gene editing efficiency in primary human chondrocyte populations Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-11 Simone Ponta, Angela Bonato, Philipp Neidenbach, Valentino F. Bruhin, Alexis Laurent, Lee Ann Applegate, Marcy Zenobi-Wong, Goncalo Barreto
CRISPR-Cas9-based genome engineering represents a powerful therapeutic tool for cartilage tissue engineering and for understanding molecular pathways driving cartilage diseases. However, primary chondrocytes are difficult to transfect and rapidly dedifferentiate during monolayer (2D) cell culture, making the lengthy expansion of a single-cell-derived edited clonal population not feasible. For this
-
Low CD4 + T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-09 Agnes Torell, Marit Stockfelt, Kaj Blennow, Henrik Zetterberg, Tansim Akhter, Dag Leonard, Lars Rönnblom, Sofia Pihl, Muna Saleh, Christopher Sjöwall, Helena Strevens, Andreas Jönsen, Anders A. Bengtsson, Estelle Trysberg, Maria Majczuk Sennström, Agneta Zickert, Elisabet Svenungsson, Iva Gunnarsson, Johan Bylund, Bo Jacobsson, Anna Rudin, Anna-Carin Lundell
Lymphopenia, autoantibodies and activation of the type I interferon (IFN) system are common features in systemic lupus erythematosus (SLE). We speculate whether lymphocyte subset counts are affected by pregnancy and if they relate to autoantibody profiles and/or IFNα protein in SLE pregnancy. Repeated blood samples were collected during pregnancy from 80 women with SLE and 51 healthy controls (HC)
-
LATS2 degradation promoted fibrosis damage and rescued by vitamin K3 in lupus nephritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-09 Chen Cheng, Hao Yang, Chan Yang, Juan Xie, Jinshen Wang, Luping Cheng, Jianfu He, Honglian Li, Haoxing Yuan, Fangfang Guo, Minmin Li, Shuwen Liu
Lupus nephritis (LN) is the most common complication of systemic lupus erythematosus (SLE). The limited treatment options for LN increase the economic burdens on patients. Because fibrotic progression leads to irreversible renal damage in LN patients and further progresses to chronic kidney disease (CKD) and the end stage of renal disease (ESRD), developing new targets to prevent LN fibrotic progression
-
Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-09 Takehiro Nakai, Nanase Honda, Eri Soga, Sho Fukui, Ayako Kitada, Naoto Yokogawa, Masato Okada
Remission is a key treatment target in systemic lupus erythematosus (SLE) management. Given the direct correlation between lupus flares and elevated risks of adverse pregnancy outcomes (APOs), securing remission before conception becomes crucial. However, the association between clinical remission with active serology, and the risk of APOs is not thoroughly understood. Additionally, determining the
-
B cell receptor repertoire analysis in primary Sjogren’s syndrome salivary glands identifies repertoire features associated with clinical activity Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-07 Ling Chang, Zihan Zheng, Yiwen Zhou, Kun Liu, Yinong Li, Bing Zhong, Zihua Zhao, Chengshun Chen, Can Qian, Qingshan Ni, Qinghua Zou, Yuzhang Wu, Jingyi Li, Liyun Zou
Primary Sjogren’s syndrome (pSS) is a complex autoimmune disease featuring damage to salivary and lacrimal glands, with the possibility of manifestations across multiple organs. Antibody-producing B cells have long been appreciated to play a significant role in pSS pathogenesis, with a number of autoreactive antibody species having been identified to be elevated in pSS patients. While several studies
-
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-05 Jianyang Liu, Helena Idborg, Marina Korotkova, Kristina Lend, Ronald van Vollenhoven, Jon Lampa, Anna Rudin, Dan Nordström, Bjorn Gudbjornsson, Gerdur Gröndal, Till Uhlig, Kim Hørslev-Petersen, Merete Lund Hetland, Mikkel Østergaard, Michael Nurmohamed, Per-Johan Jakobsson
Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient’s response to these therapies. Prostanoids, encompassing prostaglandins, prostacyclins, and thromboxanes, are potent lipid mediators implicated in RA progression. Nevertheless, the influence of DMARDs on prostanoid biosynthesis in RA
-
Vaccination and the risk of systemic lupus erythematosus: a meta-analysis of observational studies Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-04 Meijiao Wang, Huanpeng Gu, Yingqi Zhai, Xuanlin Li, Lin Huang, Haichang Li, Zhijun Xie, Chengping Wen
This meta-analysis aims to explore the potential link between vaccines and systemic lupus erythematosus (SLE). We systematically searched PubMed, Cochrane Library, and Embase for observational studies from inception to September 3, 2023, using medical subject headings (MeSH) and keywords. Study quality was assessed using the NOS scale. Statistical analyses were conducted using STATA software (version
-
Distinct uric acid trajectories are associated with incident cardiac conduction block Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-27 Na Li, Liufu Cui, Rong Shu, Haicheng Song, Jierui Wang, Shuohua Chen, Gary Tse, Nan Zhang, Xuemei Yang, Wenqi Xu, Shouling Wu, Tong Liu
The association of longitudinal uric acid (UA) changes with cardiac conduction block risk is unclear. We aimed to identify the trajectories of UA and explore its association with cardiac conduction block. A total of 67,095 participants with a mean age of 53.12 years were included from the Kailuan cohort in Tangshan, China, who were free of cardiac conduction block and with repeated measurements of
-
Identifying functional dysregulation of NOD2 variant Q902K in patients with Yao syndrome Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-23 Jingyuan Zhang, Yi Luo, Bingxuan Wu, Xin Huang, Mengzhu Zhao, Na Wu, Junke Miao, Ji Li, Lei Zhu, Di Wu, Min Shen
The study investigated the pathogenesis of Yao syndrome (YAOS), a rare systemic autoinflammatory disease associated with the nucleotide-binding oligomerization domain containing 2 (NOD2) gene variants. RNA sequencing analyses were used to detect transcriptomic profile changes. Immunoblot and immunohistochemistry were used to examine the NOD2-mediated inflammatory signaling pathways and ELISA was used
-
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-23 Jerusalem Calvo-Gutiérrez, Clementina López-Medina, Lucía Otero-Varela, Alejandro Escudero-Contreras, Rafaela Ortega-Castro, Lourdes Ladehesa-Pineda, Cristina Campos, Pilar Bernabeu-Gonzalvez, Ana Pérez-Gómez, Alicia García-Dorta, Dolores Ruiz-Montesino, Manuel Pombo-Suarez, Inmaculada Ros-Vilamajo, Fernando Sánchez-Alonso, Isabel Castrejón
Patients with Rheumatoid Arthritis (RA) have a higher prevalence of comorbidities compared to the general population. However, the implications of multimorbidity on therapeutic response and treatment retention remain unexplored. Objectives: (a) To evaluate the impact of multimorbidity on the effectiveness of the first targeted synthetic or biologic disease-modifying antirheumatic drug (ts/bDMARD),
-
Fibroblast-like synoviocytes-derived exosomal circFTO deteriorates rheumatoid arthritis by enhancing N6-methyladenosine modification of SOX9 in chondrocytes Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-22 Guoqing Li, Yuxuan Fang, Nan Xu, Yimin Ding, Dan Liu
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes disability worldwide. Exosomes released by fibroblast-like synoviocytes in RA (RA-FLSs-Exos) play a role in the development of RA, and circular RNAs (circRNAs) are important for RA progression. This study aimed to investigate the molecular mechanisms underlying the effects of RA-FLSs-Exos in RA and identify the potential pathway
-
Single-cell RNA sequencing of submandibular gland reveals collagen type XV-positive fibroblasts as a disease-characterizing cell population of IgG4-related disease Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-20 Shigeru Tanaka, Takuya Yamamoto, Arifumi Iwata, Masahiro Kiuchi, Kota Kokubo, Tomohisa Iinuma, Takahiro Sugiyama, Toyoyuki Hanazawa, Kiyoshi Hirahara, Kei Ikeda, Hiroshi Nakajima
IgG4-related disease (IgG4-RD) is a systemic autoimmune disease with an unknown etiology, affecting single/multiple organ(s). Pathological findings include the infiltration of IgG4-producing plasma cells, obliterative phlebitis, and storiform fibrosis. Although immunological studies have shed light on the dysregulation of lymphocytes in IgG4-RD pathogenesis, the role of non-immune cells remains unclear
-
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-20 Peter M. Izmirly, Mimi Y. Kim, Philip M. Carlucci, Katherine Preisinger, Brooke Z. Cohen, Kristina Deonaraine, Devyn Zaminski, Maria Dall’Era, Kenneth Kalunian, Andrea Fava, H. Michael Belmont, Ming Wu, Chaim Putterman, Jennifer Anolik, Jennifer L. Barnas, Betty Diamond, Anne Davidson, David Wofsy, Diane Kamen, Judith A. James, Joel M. Guthridge, William Apruzzese, Deepak A. Rao, Michael H. Weisman
Leveraging the Accelerating Medicines Partnership (AMP) Lupus Nephritis (LN) dataset, we evaluated longitudinal patterns, rates, and predictors of response to standard-of-care therapy in patients with lupus nephritis. Patients from US academic medical centers with class III, IV, and/or V LN and a baseline urine protein/creatinine (UPCR) ratio ≥ 1.0 (n = 180) were eligible for this analysis. Complete
-
Targeting an inflammation-amplifying cell population can attenuate osteoarthritis-associated pain Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-17 Akshay Pandey, Mamta Singla, Ana Geller, Stuart B. Goodman, Nidhi Bhutani
Understanding of pain in osteoarthritis, its genesis, and perception is still in its early stages. Identification of precise ligand-receptor pairs that transduce pain and the cells and tissues in which they reside will elucidate new therapeutic approaches for pain management. Our recent studies had identified an inflammation-amplifying (Inf-A) cell population that is expanded in human OA cartilage
-
Regulatory T and B cells in pediatric Henoch–Schönlein purpura: friends or foes? Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-16 Anne Filleron, Renaud Cezar, Marc Fila, Nastassja Protsenko, Kathleen Van Den Hende, Eric Jeziorski, Bob Occean, Thierry Chevallier, Pierre Corbeau, Tu Anh Tran
Henoch–Schönlein purpura (HSP) is the most common immunoglobulin A-mediated systemic vasculitis in childhood. We studied immune dysregulation in HSP by analyzing regulatory T (Treg), T helper 3 (Th3), and regulatory B cell (Breg) subpopulations that might intervene in immune activation, IgA production, and HSP clinical manifestations. This prospective study included 3 groups of children: 30 HSP on
-
Lipoxygenase-derived oxylipins are enriched in anti-citrullinated protein antibody (ACPA)-positive individuals at risk for developing rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-15 Liam J. O’Neil, Vidyanand Anaparti, Tanja Winter, Irene Smolik, Xiaobo Meng, Harold M. Aukema, Hani El-Gabalawy
Rheumatoid arthritis (RA) is typically preceded by an extended preclinical period where circulating autoantibodies, particularly anti-citrullinated protein antibodies (ACPA), are detectable in the absence of clinical arthritis. Increased dietary intake of anti-inflammatory omega-3 (ω3) polyunsaturated fatty acids (PUFA) has been shown to be associated with a lower the risk of developing incident RA
-
Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-15 Laure Gossec, Brittany Humphries, Megan Rutherford, Vanessa Taieb, Damon Willems, William Tillett
Capacity to work is impacted by psoriatic arthritis (PsA). Our objective was to describe the course of work productivity and leisure activity in patients with PsA treated with biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs). A systematic literature review identified all trials and observational studies published January 1, 2010–October 22, 2021, reporting work
-
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-12 Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman
We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] who received ≥ 1 dose of Ixekizumab (IXE) over 5 years (PsO) or up to 3 years (PsA, axSpA). This integrated
-
Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-12 Kunihiro Ichinose, Shuntaro Sato, Takashi Igawa, Momoko Okamoto, Ayuko Takatani, Yushiro Endo, Sosuke Tsuji, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Shin-ya Kawashiri, Naoki Iwamoto, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Nobuyuki Yajima, Ken-Ei Sada, Yoshia Miyawaki, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Shuzo Sato, Michio Fujiwara, Atsushi Kawakami
Previous studies have shown conflicting evidence regarding the incidence of cancer in patients with systemic lupus erythematosus (SLE) compared with that in healthy individuals. Calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus have been widely used to treat SLE; however, their effects on cancer risk remain unclear. We aimed to investigate the incidence of cancer in patients with SLE
-
Large-scale integrative analysis of juvenile idiopathic arthritis for new insight into its pathogenesis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-10 Daeun Kim, Jaeseung Song, Nicholas Mancuso, Serghei Mangul, Junghyun Jung, Wonhee Jang
Juvenile idiopathic arthritis (JIA) is one of the most prevalent rheumatic disorders in children and is classified as an autoimmune disease (AID). While a robust genetic contribution to JIA etiology has been established, the exact pathogenesis remains unclear. To prioritize biologically interpretable susceptibility genes and proteins for JIA, we conducted transcriptome-wide and proteome-wide association
-
Macrophage subpopulations in pediatric patients with lupus nephritis and other inflammatory diseases affecting the kidney Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-08 Mira Sandersfeld, Maike Büttner-Herold, Fulvia Ferrazzi, Kerstin Amann, Kerstin Benz, Christoph Daniel
Macrophages play an important role in the pathogenesis of lupus nephritis (LN), but less is known about macrophage subtypes in pediatric LN. Here we compared renal inflammation in LN with other inflammatory pediatric kidney diseases and assessed whether inflammation correlates with clinical parameters. Using immunofluorescence microscopy, we analyzed renal biopsies from 20 pediatric patients with lupus
-
Interaction of genetic variation at ADH1B and MLXIPL with alcohol consumption for elevated serum urate level and gout among people of European ethnicity Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-08 Min H Chuah, Megan P Leask, Ruth K Topless, Gregory D Gamble, Nicholas A Sumpter, Lisa K Stamp, Tony R Merriman, Nicola Dalbeth
Alcohol consumption is a risk factor for hyperuricaemia and gout. Multiple single-nucleotide polymorphisms (SNPs) have been identified as associated with both alcohol consumption and serum urate or gout in separate genome-wide association studies (GWAS). This study aimed to identify and characterise interactions between these shared signals of genetic association and alcohol consumption for serum urate
-
Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-08 Dubravka Ukalovic, Burkhard F. Leeb, Bernhard Rintelen, Gabriela Eichbauer-Sturm, Peter Spellitz, Rudolf Puchner, Manfred Herold, Miriam Stetter, Vera Ferincz, Johannes Resch-Passini, Jochen Zwerina, Marcus Zimmermann-Rittereiser, Ruth Fritsch-Stork
Machine learning models can support an individualized approach in the choice of bDMARDs. We developed prediction models for 5 different bDMARDs using machine learning methods based on patient data derived from the Austrian Biologics Registry (BioReg). Data from 1397 patients and 19 variables with at least 100 treat-to-target (t2t) courses per drug were derived from the BioReg biologics registry. Different
-
Manifestations and management of Sjögren’s disease Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-08 Mehrnaz Maleki-Fischbach, Liudmila Kastsianok, Matthew Koslow, Edward D. Chan
Sjögren’s disease is a heterogeneous autoimmune disorder that may be associated with systemic manifestations such as pulmonary or articular involvement. Systemic complications have prognostic implications and need to be identified and managed in a timely manner. Treatment should be tailored to the type and severity of organ involvement, ideally based on multidisciplinary evaluation.
-
Patients with obesity have more inflamed joints and higher CRP levels during the disease course in ACPA-positive RA but not in ACPA-negative RA Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-02-07 N. K. den Hollander, A. M. P Boeren, A. H. M. van der Helm-van Mil, H. W. van Steenbergen
Obese RA patients have higher disease activity scores (DAS). Previous research showed that obese RA patients have higher tender joint count (TJC) and VAS general health. However, it remains unclear whether DAS components measuring local and systemic inflammation (swollen joint count (SJC), CRP) are increased and if this is present in the total RA population or confined to an ACPA subgroup. As ACPA
-
Induction of cervical disc degeneration and discogenic pain by low concentration Propionibacterium acnes infection: an in vivo animal study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-31 Jie Li, Hui Li, Yilei Chen, Dikai Bei, Bao Huang, Kaifeng Gan, Peiming Sang, Junhui Liu, Zhi Shan, Jian Chen, Fengdong Zhao, Binhui Chen
Although cervical intervertebral disc (IVD) degeneration is closely associated with neck pain, its cause remains unclear. In this study, an animal model of cervical disc degeneration and discogenic neck pain induced by a low concentration of Propionibacterium acnes (P. acnes-L) is investigated to explore the possible mechanisms of cervical discogenic pain. Cervical IVD degeneration and discitis was
-
Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-31 Yu Lu, Jianyu Zhang, Hejun Li, Ting Li
The association between non-alcoholic fatty liver disease (NAFLD) and osteoarthritis (OA) has not been well elucidated. The aim of the present study was to investigate the association between NAFLD and OA in the US adults. A cross-sectional study was performed on participants in the 2017–2018 National Health and Nutrition Examination Survey (NHANES) cycle. NAFLD was defined by the vibration-controlled
-
Correction: CircPTPN22 modulates T‑cell activation by sponging miR‑4689 to regulate S1PR1 expression in patients with systemic lupus erythematosus Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-31 Zhuyan Jiang, Shifei Li, Yuying Jia, Qijun Wu, Xuemeng Chen, Mengjie Zhang, Qingqing Miao, Zhiting Zhong, Zhifang Zhai, Bing Ni, Jun Xiao, Jun Tang
Correction: Arthritis Res Ther 25, 206 (2023) https://doi.org/10.1186/s13075-023-03150-3 Following publication of the original article [1], the authors reported an error found in the first affiliation. The “Division of Life Sciences and Medicine” should come after “The First Affiliated Hospital of USTC” and this is currently not correct. The affiliation should be: “Dermatology Department of The First
-
Interaction of 5-HTTLPR and SLE disease status on resting-state brain function Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-31 Lihua Ma, Yifan Yang, Shu Li, Bibhuti Upreti, Shuang Liu, Xiangyu Wang, Ru Bai, Yuqi Cheng, Jian Xu
Neuropsychiatric involvement in systemic lupus erythematosus (SLE) is a common clinical manifestation. In SLE patients, cerebral function is a more sensitive predictor of central nervous system damage, and abnormalities in cerebral function may be apparent before substantial neuropsychiatric symptoms occur. The 5-hydroxynyptamine(5-HT) system has the ability to interact with the majority of the neurochemical
-
Apolipoproteins and the risk of giant cell arteritis—a nested case–control study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-27 Karin Wadström, Lennart T. H. Jacobsson, Aladdin J. Mohammad, Kenneth J. Warrington, Eric L. Matteson, Carl Turesson
The etiology of giant cell arteritis (GCA) and its predictors are incompletely understood. Previous studies have indicated reduced risk of future development of GCA in individuals with obesity and/or diabetes mellitus. There is limited information on blood lipids before the onset of GCA. The objective of the study was to investigate the relation between apolipoprotein levels and future diagnosis of
-
Endoplasmic reticulum aminopeptidase 2 regulates CD4+ T cells pyroptosis in rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-25 Jianhua Zhang, Hao Cai, Weiwei Sun, Weijie Wu, Yunyi Nan, Yingchen Ni, Xinyuan Wu, Minhao Chen, Hua Xu, Youhua Wang
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease with a complex pathogenesis that has not yet been fully elucidated, and T-cell pyroptosis is an important pathogenetic factor in RA. This study aimed to investigate the role of endoplasmic reticulum aminopeptidase 2 (ERAP2) in the pyroptosis of CD4+ T cells in RA and the specific molecular mechanism. Peripheral venous blood was
-
Exploring the causal association between rheumatoid arthritis and the risk of cervical cancer: a two-sample Mendelian randomization study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-23 Minxian Xu, Huan Chen, Tao Tan, Kaihong Xie, Hui Xie, Qing Li
Whether rheumatoid arthritis patients have an increased risk of cervical cancer remains controversial, and further research is needed on this clinical question. This study aims to investigate the association between rheumatoid arthritis and the susceptibility to cervical cancer by employing Mendelian randomization methodology, utilizing the extensive dataset from human genome-wide association data
-
Correction: Iguratimod attenuated fbrosis in systemic sclerosis via targeting early growth response 1 expression Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-22 Lichong Shen, Hanlin Yin, Li Sun, Zhiliang Zhang, Yuyang Jin, Shan Cao, Qiong Fu, Chaofan Fan, Chunde Bao, Liangjing Lu, Yifan Zhan, Xiaojiang Xu, Xiaoxiang Chen, Qingran Yan
Correction: Arthritis Res Ther 25, 151 (2023) https://doi.org/10.1186/s13075-023-03135-2 Following publication of the original article [1], the authors reported an error found in the Funding section, the grant number for Shanghai Municipal Commission of Health and Family Planning is incorrect. This should be corrected from “20204Y0088” to “20204Y0090”. The original article [1] has been updated. Shen
-
Tetraspanin profiles of serum extracellular vesicles reflect functional limitations and pain perception in knee osteoarthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-22 Anne-Mari Mustonen, Mari Palviainen, Laura Säisänen, Lauri Karttunen, Sylvain Tollis, Amir Esrafilian, Jusa Reijonen, Petro Julkunen, Pia R-M Siljander, Heikki Kröger, Jussi Mäki, Jari Arokoski, Petteri Nieminen
Emerging evidence suggests that extracellular vesicles (EVs) can play roles in inflammatory processes and joint degradation in primary osteoarthritis (OA), a common age-associated joint disease. EV subpopulations express tetraspanins and platelet markers that may reflect OA pathogenesis. The present study investigated the associations between these EV surface markers and articular cartilage degradation
-
PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-01-22 Johanna Straube, Shoiab Bukhari, Shalom Lerrer, Robert J. Winchester, Yevgeniya Gartshteyn, Brian S. Henick, Matthew A. Dragovich, Adam Mor
PD-1 is an immune checkpoint on T cells, and interventions to block this receptor result in T cell activation and enhanced immune response to tumors and pathogens. Reciprocally, despite a decade of research, approaches to treat autoimmunity with PD-1 agonists have only had limited successful. To resolve this, new methods must be developed to augment PD-1 function beyond engaging the receptor. We conducted